Table 3 |
||
|
Vectors used for human gene therapy trials |
||
| Vector |
Number of trials |
Percentage of total trials |
|
|
||
| Adenovirus |
331 |
24.7 |
| Retrovirus |
305 |
22.8 |
| Vaccinia |
91 |
6.8 |
| Poxviruses |
86 |
6.4 |
| Adeno-associated virus |
47 |
3.5 |
| Herpes simplex virus |
42 |
3.2 |
| Nonviral |
343 |
25.6 |
| Other |
93 |
7.0 |
| Total |
1,338 |
100 |
|
|
||
|
Sourced from [11]. |
||
|
Evans et al. Arthritis Research & Therapy 2008 10:110 doi:10.1186/ar2411 |
||